Capital One Financial Research Analysts Lift Earnings Estimates for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Analysts at Capital One Financial upped their FY2025 EPS estimates for Ironwood Pharmaceuticals in a research note issued on Wednesday, May 1st. Capital One Financial analyst T. Chiang now expects that the biotechnology company will post earnings of $0.88 per share for the year, up from their previous estimate of $0.85. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.71 per share.

Several other equities research analysts have also commented on IRWD. StockNews.com lowered Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, April 6th. Wells Fargo & Company reduced their price target on Ironwood Pharmaceuticals from $20.00 to $14.00 and set an “overweight” rating for the company in a research report on Friday, March 1st. Piper Sandler raised their price objective on Ironwood Pharmaceuticals from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. Finally, Craig Hallum started coverage on Ironwood Pharmaceuticals in a research note on Wednesday, January 17th. They set a “buy” rating and a $21.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.80.

Ironwood Pharmaceuticals Trading Down 2.2 %

IRWD opened at $8.12 on Friday. The firm’s 50 day simple moving average is $8.82 and its two-hundred day simple moving average is $10.61. The company has a market capitalization of $1.27 billion, a PE ratio of -1.25 and a beta of 0.57. Ironwood Pharmaceuticals has a 1-year low of $7.53 and a 1-year high of $15.70.

Insiders Place Their Bets

In other news, SVP Andrew Davis sold 9,846 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $15.24, for a total value of $150,053.04. Following the transaction, the senior vice president now directly owns 208,324 shares in the company, valued at $3,174,857.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Jon R. Duane bought 6,920 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The stock was purchased at an average price of $8.70 per share, for a total transaction of $60,204.00. Following the completion of the transaction, the director now owns 121,028 shares in the company, valued at $1,052,943.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Andrew Davis sold 9,846 shares of the firm’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $15.24, for a total transaction of $150,053.04. Following the transaction, the senior vice president now directly owns 208,324 shares of the company’s stock, valued at $3,174,857.76. The disclosure for this sale can be found here. In the last quarter, insiders sold 273,008 shares of company stock worth $4,160,642. Corporate insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Signaturefd LLC grew its holdings in shares of Ironwood Pharmaceuticals by 61.4% in the fourth quarter. Signaturefd LLC now owns 2,160 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 822 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in Ironwood Pharmaceuticals by 331.6% during the fourth quarter. Daiwa Securities Group Inc. now owns 2,473 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,900 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Ironwood Pharmaceuticals by 96.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,997 shares of the biotechnology company’s stock worth $38,000 after buying an additional 1,961 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Ironwood Pharmaceuticals by 152.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock worth $50,000 after buying an additional 2,645 shares during the last quarter. Finally, Headlands Technologies LLC raised its position in shares of Ironwood Pharmaceuticals by 396.5% during the 3rd quarter. Headlands Technologies LLC now owns 6,737 shares of the biotechnology company’s stock valued at $65,000 after buying an additional 5,380 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.